<p>Clearside Biomedical (CLSD) 的股票在周一暴跌，此前这家生物制药公司宣布自愿申请第 11 章破产。公司表示，其董事会在评估所有战略选项后做出了申请破产的决定。</p>
<h3>TipRanks 黑色星期五促销</h3>
<ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取您投资所需的数据支持洞察和研究工具。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>Clearside Biomedical 打算在破产过程中出售其全部或部分资产。这将要求有意向的各方提交对其资产或业务的有约束力的报价。Clearside Biomedical 指出，这将不受任何留置权和权益的限制。公司还向破产法院申请在此期间继续正常运营的许可。</p>
<p>Clearside Biomedical 的总裁兼首席执行官 George Lasezkay 表示：&#34;我们相信，基于我们经过临床验证的 SCS 微注射器平台及相关知识产权、成功的脉络膜上 CLS-AX（阿西替尼注射悬液）临床开发项目、多项脉络膜上许可协议及其他相关资产，我们拥有有吸引力的资产。&#34;</p>
<h2><strong>Clearside Biomedical 今日股票走势</strong></h2>
<p>Clearside Biomedical 的股票在周一的盘前交易中下跌了 70.59%，此前在周五上涨了 4.21%。截至目前，该股年初至今已下跌 80.91%，过去 12 个月下跌 83.21%。</p>
<p>随着今天破产消息的发布，CLSD 股票交易活跃。截至撰写时，交易量超过 774,000 股，而三个月的日均交易量约为 64,390 股。</p>

Clearside生物医学

CLSDQ

<p>Clearside Biomedical (CLSD) 的股票在公司宣布自愿申请第 11 章破产后大幅下跌。董事会在评估战略选项后做出了这一决定。Clearside 计划在破产过程中出售其资产，并已请求继续运营。该股票在盘前交易中下跌了 70.59%，并且交易活动非常活跃</p>

<p>Clearside Biomedical (CLSD) stock plummeted on Monday after the biopharmaceutical company announced its voluntary filing for Chapter 11 bankruptcy. The company said its Board of Directors made the decision to file for bankruptcy after having evaluated all strategic options.</p>
<div class="lb-trans"><p>Clearside Biomedical (CLSD) 的股票在周一暴跌，此前这家生物制药公司宣布自愿申请第 11 章破产。公司表示，其董事会在评估所有战略选项后做出了申请破产的决定。</p>
</div><h3>TipRanks Black Friday Sale</h3>
<div class="lb-trans"><h3>TipRanks 黑色星期五促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申请 TipRanks Premium 享受 60% 的折扣，获取您投资所需的数据支持洞察和研究工具。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>Clearside Biomedical intends to pursue the sale of all or part of its assets during the bankruptcy process. This will require interested parties to submit binding offers for its assets or business. Clearside Biomedical notes this would be free and clear of liens and interests. The company has also sought permission from the bankruptcy court to continue normal operations during this period.</p>
<div class="lb-trans"><p>Clearside Biomedical 打算在破产过程中出售其全部或部分资产。这将要求有意向的各方提交对其资产或业务的有约束力的报价。Clearside Biomedical 指出，这将不受任何留置权和权益的限制。公司还向破产法院申请在此期间继续正常运营的许可。</p>
</div><p>George Lasezkay, President and CEO of Clearside Biomedical, said, &#34;We believe that we have attractive assets based on our clinically proven SCS Microinjector platform and associated intellectual property, our successful suprachoroidal CLS-AX (axitinib injectable suspension) clinical development program, multiple suprachoroidal licensing agreements and other related assets.&#34;</p>
<div class="lb-trans"><p>Clearside Biomedical 的总裁兼首席执行官 George Lasezkay 表示：&#34;我们相信，基于我们经过临床验证的 SCS 微注射器平台及相关知识产权、成功的脉络膜上 CLS-AX（阿西替尼注射悬液）临床开发项目、多项脉络膜上许可协议及其他相关资产，我们拥有有吸引力的资产。&#34;</p>
</div><h2><strong>Clearside Biomedical Stock Movement Today</strong></h2>
<div class="lb-trans"><h2><strong>Clearside Biomedical 今日股票走势</strong></h2>
</div><p>Clearside Biomedical stock was down 70.59% in pre-market trading on Monday, following a 4.21% rally on Friday. The shares have decreased 80.91% year-to-date and 83.21% over the past 12 months.</p>
<div class="lb-trans"><p>Clearside Biomedical 的股票在周一的盘前交易中下跌了 70.59%，此前在周五上涨了 4.21%。截至目前，该股年初至今已下跌 80.91%，过去 12 个月下跌 83.21%。</p>
</div><p>With today's bankruptcy news came heavy trading of CLSD stock. This saw more than 774,000 shares traded as of this writing, compared to a three-month daily average of about 64,390 units.</p>
<div class="lb-trans"><p>随着今天破产消息的发布，CLSD 股票交易活跃。截至撰写时，交易量超过 774,000 股，而三个月的日均交易量约为 64,390 股。</p>
</div>

Clearside 生物医学的股票（CLSD）今天为何下跌？